{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T16:10:56Z","timestamp":1762272656506,"version":"build-2065373602"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:00:00Z","timestamp":1609372800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Diabetes and its Complications"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.jdiacomp.2020.107831","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T02:28:43Z","timestamp":1609381723000},"page":"107831","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Target attainment in insulin-naive patients at high risk for hypoglycemia: Results from ACHIEVE Control"],"prefix":"10.1016","volume":"35","author":[{"given":"John","family":"Anderson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Meneghini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debbie","family":"Hinnen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jasvinder","family":"Gill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathieu","family":"Coudert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Evenou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Medha","family":"Munshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jdiacomp.2020.107831_bb0005","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0010","doi-asserted-by":"crossref","unstructured":"American Diabetes Association. 6. Glycemic targets: standards of medical care in diabetes-2020. Diabetes Care. 2020;43:S66-S76. doi: https:\/\/doi.org\/10.2337\/dc20-S006.","DOI":"10.2337\/dc20-S006"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0015","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s12325-014-0120-1","article-title":"Much ado about nothing? A real-world study of patients with type 2 diabetes switching basal insulin analogs","volume":"31","author":"Wei","year":"2014","journal-title":"Adv Ther"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0020","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1080\/00325481.2019.1568136","article-title":"Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes","volume":"131","author":"Hompesch","year":"2019","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0025","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2337\/dc14-0006","article-title":"New insulin glargine 300 Units\u00b7mL\u22121 provides a more even activity profile and prolonged glycemic control at steady state compared with insulin glargine 100 Units\u00b7mL\u22121","volume":"38","author":"Becker","year":"2015","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0030","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1007\/s12325-019-00925-6","article-title":"Differentiating basal insulin preparations: understanding how they work explains why they are different","volume":"36","author":"Cheng","year":"2019","journal-title":"Adv Ther"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0035","doi-asserted-by":"crossref","DOI":"10.1136\/bmjdrc-2015-000154","article-title":"Understanding CKD among patients with T2DM: prevalence, temporal trends, and treatment patterns-NHANES 2007\u20132012","volume":"4","author":"Wu","year":"2016","journal-title":"BMJ Open Diabetes Res Care"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0040","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3390\/jcm4050948","article-title":"Hypoglycemia in patients with diabetes and renal disease","volume":"4","author":"Alsahli","year":"2015","journal-title":"J Clin Med"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0045","doi-asserted-by":"crossref","unstructured":"Frias J, Evenou P, Dalton D, Dungan K. Insulin Glargine 300 U\/mL Versus First-generation Basal Insulins in Insulin-naive Type 2 Diabetes Patients With and Without Cardiovascular Disease: Outcomes of the Randomized Pragmatic Real-life Clinical Trial ACHIEVE Control. Presented at: American Diabetes Association 79th Scientific Sessions; June 7\u201311, 2019; San Francisco, CA, USA.","DOI":"10.2337\/db19-128-LB"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0050","doi-asserted-by":"crossref","first-page":"f4533","DOI":"10.1136\/bmj.f4533","article-title":"Severe hypoglycaemia and cardiovascular disease: systematic review and meta-analysis with bias analysis","volume":"347","author":"Goto","year":"2013","journal-title":"BMJ."},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0055","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1056\/NEJMoa1003795","article-title":"Severe hypoglycemia and risks of vascular events and death","volume":"363","author":"Zoungas","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0060","doi-asserted-by":"crossref","first-page":"156","DOI":"10.14336\/AD.2014.0330","article-title":"Hypoglycemia in older people \u2013 a less well recognized risk factor for frailty","volume":"6","author":"Abdelhafiz","year":"2015","journal-title":"Aging Dis"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0065","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.2337\/dc12-1801","article-title":"Diabetes in older adults","volume":"35","author":"Kirkman","year":"2012","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0070","first-page":"1110","article-title":"Association of hypoglycemia with subsequent dementia in older patients with type 2 diabetes mellitus","volume":"72","author":"Mehta","year":"2017","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0075","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jama.2009.460","article-title":"Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus","volume":"301","author":"Whitmer","year":"2009","journal-title":"JAMA."},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0080","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3803\/EnM.2017.32.2.195","article-title":"Hypoglycemia and dementia","volume":"32","author":"Rhee","year":"2017","journal-title":"Endocrinol Metab"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0085","doi-asserted-by":"crossref","first-page":"S109","DOI":"10.3233\/JAD-132570","article-title":"Severe diabetic retinal disease and dementia risk in type 2 diabetes","volume":"42","author":"Exalto","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0090","doi-asserted-by":"crossref","first-page":"224","DOI":"10.2337\/ds16-0035","article-title":"Management of adults with diabetes and cognitive problems","volume":"29","author":"Hopkins","year":"2016","journal-title":"Diabetes Spectr"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0095","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1464-5491.2010.03142.x","article-title":"Self management and patient understanding of diabetes in the older person","volume":"28","author":"Hewitt","year":"2011","journal-title":"Diabet Med"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0100","first-page":"7","article-title":"The influence of cognition on self-management of type 2 diabetes in older people","volume":"9","author":"Tomlin","year":"2016","journal-title":"Psychol Res Behav Manag"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0105","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1001\/archinte.161.13.1653","article-title":"Hypoglycemia in patients with type 2 diabetes mellitus","volume":"161","author":"Miller","year":"2001","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0110","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jdiacomp.2016.12.014","article-title":"Fu H. Association between mild and severe hypoglycemia in people with type 2 diabetes initiating insulin","volume":"31","author":"Festa","year":"2017","journal-title":"J Diabetes Complications"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0115","article-title":"A pragmatic randomised clinical trial of insulin glargine 300 U\/mL vs first-generation basal insulin analogues in insulin-n\u00e4ive patients with type 2 diabetes: ACHIEVE Control","author":"Meneghini","year":"2020","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0125","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1080\/00325481.2016.1241663","article-title":"Achieve control: a pragmatic clinical trial of insulin glargine 300 U\/mL versus other basal insulins in insulin-na\u00efve patients with type 2 diabetes","volume":"128","author":"Oster","year":"2016","journal-title":"Postgrad Med"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0135","unstructured":"Comprehensive diabetes care. National Committee for Quality Assurance website; 2020. https:\/\/www.ncqa.org\/hedis\/measures\/comprehensive-diabetes-care\/."},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0140","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1111\/dom.13673","article-title":"The Diabetes Unmet Need with Basal Insulin Evaluation (DUNE) study in type 2 diabetes: achieving HbA1c targets with basal insulin in a real-world setting","volume":"21","author":"Meneghini","year":"2019","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0145","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.diabet.2018.02.002","article-title":"Clinical perspectives from the BEGIN and EDITION programmes: trial-level meta-analyses outcomes with either degludec or glargine 300U\/mL vs glargine 100U\/mL in T2DM","volume":"44","author":"Roussel","year":"2018","journal-title":"Diabetes Metab"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0150","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1007\/s13300-019-0568-8","article-title":"Rates of hypoglycemia predicted in patients with type 2 diabetes on insulin glargine 300 U\/ml versus first- and second-generation basal insulin analogs: the real-world LIGHTNING study","volume":"10","author":"Pettus","year":"2019","journal-title":"Diabetes Ther"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0155","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/jama.2017.7117","article-title":"Effect of insulin degludec vs insulin glargine U100 on hypoglycemia in patients with type 2 diabetes: the SWITCH 2 randomized clinical trial","volume":"318","author":"Wysham","year":"2017","journal-title":"JAMA."},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0160","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.2337\/dc18-0559","article-title":"More similarities than differences testing insulin glargine 300 units\/mL versus insulin degludec 100 units\/mL in insulin-naive type 2 diabetes: the randomized head-to-head BRIGHT trial","volume":"41","author":"Rosenstock","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb0165","doi-asserted-by":"crossref","unstructured":"Charbonnel B, Aroda VR, Westerbacka J, Lauand Sr. F, Boelle E, Cheng AY, et al. Differences in HbA1c Reduction Between Insulin Glargine 300 U\/mL (Gla-300) and Insulin Degludec 100 U\/mL (IDeg-100) in Adults \u226570 Years of Age With T2DM in the BRIGHT Trial [Abstract 131-LB]. Presented at: American Diabetes Association 79th Scientific Sessions; June 7\u201311, 2019; San Francisco, CA, USA.","DOI":"10.2337\/db19-131-LB"},{"year":"2019","series-title":"Differences in HbA1c Lowering Effect and Hypoglycemia Risk Between Gla-300 and IDeg According to Renal Function in the BRIGHT Trial [Abstract 146-OR]. Presented at: American Diabetes Association 79th Scientific Sessions; June 7\u201311","author":"Haluz\u00edk","key":"10.1016\/j.jdiacomp.2020.107831_bb0170"},{"key":"10.1016\/j.jdiacomp.2020.107831_bb9000","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/dom.12438","article-title":"New insulin glargine 300 U\/ml compared with glargine 100 U\/ml in insulin-na\u00efve people with type 2 diabetes on oral glucose-lowering drugs: a randomized controlled trial (EDITION 3)","volume":"17","author":"Bolli","year":"2015","journal-title":"Diabetes Obes Metab."}],"container-title":["Journal of Diabetes and its Complications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872720306322?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056872720306322?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:12:50Z","timestamp":1761005570000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056872720306322"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["S1056872720306322"],"URL":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107831","relation":{},"ISSN":["1056-8727"],"issn-type":[{"type":"print","value":"1056-8727"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Target attainment in insulin-naive patients at high risk for hypoglycemia: Results from ACHIEVE Control","name":"articletitle","label":"Article Title"},{"value":"Journal of Diabetes and its Complications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdiacomp.2020.107831","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors.","name":"copyright","label":"Copyright"}],"article-number":"107831"}}